Show simple item record

FieldValueLanguage
dc.contributor.authorLipworth, W
dc.date.accessioned2015-12-11
dc.date.available2015-12-11
dc.date.issued2015-12-10
dc.identifier.citationWendy Lipworth Regulations have improved since thalidomide but drug scares are still possible The Conversation 2015en_AU
dc.identifier.urihttp://hdl.handle.net/2123/14133
dc.descriptionthe Conversation articleen_AU
dc.description.abstractThe thalidomide tragedy, which resulted in thousands of deaths and disabilities in the late 1950s and early 1960s, changed medicine forever. One of its outcomes was the establishment of more robust mechanisms for the regulation of medicines and medical devices. Regulatory bodies – including the Therapeutic Goods Administration (TGA) in Australia, the Food and Drug Administration (FDA) in the United States and the Medicines and Health care products Regulatory Agency (MHRA) in the United Kingdom – now decide which products pharmaceutical and medical device companies can market. They also monitor the safety of medicines and devices once they are on the market. There is no doubt that the tightening of regulation has prevented countless deaths and disabilities, and saved many lives. But regulation cannot always protect us from harm and events disturbingly similar to the thalidomide tragedy continue to occur. Let’s look at two recent examples.en_AU
dc.description.sponsorshipNHMRC Career Development Fellowship APP1063569en_AU
dc.language.isoen_AUen_AU
dc.publisherThe Conversationen_AU
dc.titleRegulations have improved since thalidomide but drug scares are still possibleen_AU
dc.typeArticleen_AU


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.